Informed Consent Discussions and Diagnostic Uncertainty

Kasem Jamil Al-Saloumi details the various uncertainties surrounding molecular and genetic tests, and argues that patients should be aware of the questions these uncertainties raise before they undergo testing.

__________________________________________

A patient agrees to a molecular test because the question sounds simple: Is something there or not? The result arrives, and the answer is technically “yes” — a sequence, a variant, a signal — but clinically, the meaning is uncertain. The test has detected something. It has not necessarily explained the illness, predicted the future, or established what should happen next. At that moment, the ethical problem is not only how the result is interpreted. It is whether the patient was prepared for this possibility before testing began.

Genetics provides an important model. Professional guidance from the American College of Medical Genetics and Genomics (ACMG) recognizes limitations, possible outcomes, uncertain interpretation and later reinterpretation as legitimate parts of informed consent. Genetic counsellors can help patients understand that a result can be probabilistic, incomplete or subject to revision. The challenge then is not that medicine has forgotten how to navigate uncertainty. The harder question is what happens when increasingly sensitive molecular testing expands beyond settings where specialist counselling is built into the pathway.

Photo Credit: Gerd Altmann/publicdomainpictures.net. Image Description: A computer generated image of a DNA.

That matters because “more detectable” does not always mean “more knowable.” Genome and exome sequencing can produce findings whose clinical significance changes as evidence evolves. Consumer-directed genomic testing can place complex probabilities in front of people outside a traditional genetics clinic. High-sensitivity microbial sequencing creates a different but related problem: detecting microbial DNA may still leave open whether the signal reflects reagent or laboratory contamination, background DNA or a finding unrelated to the patient’s symptoms. Different technologies create different uncertainties, but the ethical pattern is similar. A technically real signal can outrun its clinical meaning.

Consent should therefore do more than list “false positives” or “uncertain results” as items in a long form. A warning label is not the same as preparation. Patients should know, in ordinary language, what an ambiguous result could mean for them: that follow-up testing may be needed; that no immediate treatment may follow; that an interpretation may later change; and that choosing to test can create a new decision rather than close an old one.

This is especially important because uncertainty has a psychological and practical cost for patients. Once a finding is placed in a medical record or delivered to a patient or substitute decision-maker, it can carry more weight than the evidence that supports it. People may reasonably hear “DNA was found” or “a variant was detected” as “the cause has been identified.” Clinicians may later correct that impression, but ethically robust consent should try to prevent the misunderstanding rather than repair it afterward.

There is also a responsibility question. If interpretation can change, who owns the uncertainty after the test? ACMG guidance on re-contact describes re-contact as a shared responsibility among the laboratory, healthcare provider, and patient. That is a useful principle, but it only works if the patient knows that there may be something worth revisiting. Informed consent discussions should explain not only what the test can reveal today, but whether results may be reanalysed, who may initiate re-contact, and what the patient should do if their clinical or family context changes.

None of these things mean that every molecular test requires a lengthy genetic-counselling session. The requirements for informed consent should match the test and the stakes. But complexity should not disappear merely because a test becomes routine, automated, or easy to order. When a test can generate information that is difficult to interpret, the consent process should contain a plan for uncertainty as well as a description of possibility.

The ACMG framework for genomic screening already expects informed consent to address limitations, possible outcomes and changing interpretations. The ethical task is to carry that preparation into the settings where molecular tests are offered. Meaningful informed consent should help a person anticipate the kinds of decisions a test may create — including the uncomfortable possibility that the laboratory can find a signal before medicine can confidently say what it means.

 __________________________________________

Kasem Jamil Al-Saloumi is a biology educator and scientific research coordinator in Doha, Qatar.